| Literature DB >> 33518809 |
Saad A Alkahtani1, Ashraf M Mahmoud2,3, Mater H Mahnashi2, Ali O AlQarni2, Yahya S A Alqahtani2, Mohamed M El-Wekil3.
Abstract
In this study, zinc sulfide nanoparticles were loaded on reduced graphene oxide (ZnS NPs/rGO) using simple sonochemical method. The nanocomposite was characterized using different morphological and electrochemical techniques such as TEM, SEM, PXRD, EDX, Raman spectroscopy, FTIR, N2-adsorption-desorption, CV, and EIS. The ZnS NPs/rGO modified glassy carbon electrode (GCE) was used to simultaneously estimate hydroxychloroquine (HCQ) and daclatasvir (DAC) in a binary mixture for the first time. The modified nanocomposite exhibited good catalytic activity towards HCQ and DAC detection. In addition, it showed higher sensitivity, good selectivity and stability; and high reproducibility towards HCQ and DAC analysis. The activity of the modified electrode was noticeably improved due to synergism between ZnS NPs and rGO. Under optimum conditions of DPV measurements, the anodic peak currents (Ipa) were obviously increased with the increase of HCQ and DAC amounts with linear ranges of 5.0-65.0 and 7.0-65.0 nM with LODs of 0.456 and 0.498 nM for HCQ and DAC, respectively. The ZnS NPs/ rGO modified GCE was used to quantify HCQ and DAC in biological fluids with recoveries of 98.7-102.7% and 96.9-104.5% and RSDs of 1.89-3.57% and 1.91-3.70%, respectively.Entities:
Keywords: Daclatasvir; Hydroxychloroquine; Reduced graphene oxide; Sonochemical synthesis; Zinc sulfide nanoparticles
Year: 2021 PMID: 33518809 PMCID: PMC7826116 DOI: 10.1016/j.microc.2021.105972
Source DB: PubMed Journal: Microchem J ISSN: 0026-265X Impact factor: 4.821
Scheme 1Representative diagram for preparation of ZnS NPs@rGO/GCE and electrochemical oxidation of HCQ and DAC.
Fig. 1CVs of 50 µM HCQ and DAC at bare GCE (a), ZnS NPS/GCE (b), rGO/GCE (c) and ZnS NPs@rGO/GCE (d) in B.R. buffer (pH 5.5) at scan rate of 40 mV s−1 after preconcentration time of 180 s.
Scheme 2The interaction mechanisms between DAC, HCQ and ZnS NPs@rGO.
Fig. 2DPV scans of 10.0 nM HCQ and DAC at ZnS NPs@rGO/GCE.
Fig. 3DPV scans for various concentrations of HCQ (A) and DAC (B) at fixed concentrations of 10.0 nM DAC and 10.0 nM HCQ, respectively. HCQ concentrations (1–12): 5.0–65.0 nM. DAC concentrations (1–12): 7.0–65.0 nM. (C) DPV scans of mixture solution of HCQ and DAC obtained at the modified electrode. At right sides are the corresponding calibration plots. Conditions: Step height, pulse height, pulse width, pulse period and preconcentration time are 0.25 V, 0.35 V, 0.15 V, 0.6 s and 150 s.
Analytical parameters for voltammetric determination of HCQ and DAC obtained at ZnS NPs@rGO/GCE.
| Sample | Linear range (nM) | Regression equation | LOQ (nM) | LOD (nM) |
|---|---|---|---|---|
| (A) HCQ | 5.0–65.0 | Ipa (µA) = 4.58 + 1.01 CHCQ | 1.18 | 0.392 |
| (B) DAC | 7.0–65.0 | Ipa (µA) = 1.67 + 0.96 CDAC | 1.15 | 0.382 |
| (C) HCQ and DAC simultaneously | ||||
| HCQ | 5.0–65.0 | Ipa (µA) = 5.28 + 0.99 CHCQ | 1.51 | 0.498 |
| DAC | 7.0–65.0 | Ipa (µA) = 1.38 + 0.98CDAC | 1.36 | 0.456 |
List of various HCQ and DAC sensors reported vs. ZnS NPs@rGO/GCE.
| Electrodes | Technique | Linearity range (nM) | LOD (nM) | Samples | Reference |
|---|---|---|---|---|---|
| Bare glassy carbon | DPV | 20 × 103-500 × 103 | 11.2 × 103 | Tablets | |
| Cathodic treated boron diamond | SWV | 290–5660 | 180 | Tablets and synthetic urines | |
| N,N′-bis[(E)-(1-pyridyl) methylidene]-1,3-propanediamine modified GCE | DPV | 90–1021 | 4.5 | Human serum | |
| Schiff’s base modified GCE | DPV | 7–11900 | 4.7 | Bulk | |
| Carbon nanotube/nickel nanoparticle/GCE | SWV | 24–300 × 103 | 15.82 | Tablet, serum | |
| Molecularly imprinted polymer/reduced graphene oxide--based carbon-paste sensor | CV | 0.04–812 | 0.012 | Plasma and urine | |
| Chitosan /multi-walled carbon nanotubes and cobalt nanoparticles/carbon paste electrode | DPV | 1–12000 | 0.88 | Tablet, urine and serum | |
| ZnS NPs@rGO/GCE | DPV | 7.0–65.0 (DAC) 5.0–65.0 (HCQ) | 0.498(DAC) 0.456(HCQ) | Plasma and urine | This work |
Analysis of HCQ and DAC by ZnS NPs@rGO/GCE in human plasma and urine samples (n = 3).
| Samples | Added(nM) | Proposed sensor | HPLC method | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAC | HCQ | DAC | HCQ | ||||||||||
| Plasma 1 | Found(nM) | Recovery %±SD | RSD % | Found(nM) | Recovery %±SD | RSD % | Found(nM) | Recovery %±SD | RSD % | Found(nM) | Recovery %±SD | RSD % | |
| 10.0 | 9.98 | 99.8 ± 3.12 | 3.13 | 9.95 | 99.5 ± 2.85 | 2.86 | 9.87 | 98.7 ± 4.18 | 4.23 | 10.13 | 101.3 ± 3.98 | 3.92 | |
| 30.0 | 31.34 | 104.5 ± 3.87 | 3.70 | 30.80 | 102.7 ± 2.27 | 2.21 | 30.34 | 101.1 ± 5.23 | 5.17 | 28.92 | 96.4 ± 3.86 | 4.00 | |
| Plasma 2 | |||||||||||||
| 15.0 | 15.08 | 100.5 ± 2.87 | 2.87 | 14.97 | 99.8 ± 1.89 | 1.89 | 14.87 | 99.1 ± 2.98 | 3.00 | 14.92 | 99.5 ± 4.72 | 4.74 | |
| 40.0 | 38.78 | 96.9 ± 3.37 | 3.48 | 40.12 | 100.3 ± 2.49 | 2.48 | 40.56 | 101.4 ± 3.89 | 3.84 | 38.87 | 97.2 ± 3.78 | 3.88 | |
| Urine 1 | |||||||||||||
| 10.0 | 9.87 | 98.7 ± 2.95 | 2.99 | 10.45 | 98.7 ± 3.12 | 3.16 | 10.15 | 101.5 ± 2.64 | 2.60 | 9.56 | 95.6 ± 3.34 | 3.49 | |
| 30.0 | 29.45 | 98.2 ± 3.51 | 3.57 | 30.34 | 101.1 ± 3.61 | 3.57 | 30.67 | 102.2 ± 3.10 | 3.06 | 29.23 | 97.4 ± 3.87 | 3.97 | |
| Urine 2 | |||||||||||||
| 15.0 | 15.23 | 101.5 ± 2.76 | 2.72 | 15.27 | 101.8 ± 3.32 | 3.26 | 14.57 | 97.1 ± 4.78 | 4.92 | 15.47 | 103.1 ± 3.55 | 3.44 | |
| 30.0 | 30.89 | 102.9 ± 1.97 | 1.91 | 29.65 | 98.8 ± 2.78 | 2.81 | 29.45 | 98.1 ± 4.67 | 4.76 | 30.35 | 101.1 ± 2.85 | 2.82 | |